{"nctId":"NCT00657709","briefTitle":"Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","startDateStruct":{"date":"2008-03"},"conditions":["Serogroup B Meningococcal Meningitis"],"count":3630,"armGroups":[{"label":"rMenB Lot1","type":"EXPERIMENTAL","interventionNames":["Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)"]},{"label":"rMenB Lot2","type":"EXPERIMENTAL","interventionNames":["Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)"]},{"label":"rMenB Lot3","type":"EXPERIMENTAL","interventionNames":["Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)"]},{"label":"Routine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Infanrix Hexa","Biological: Prevenar"]},{"label":"MenC + Routine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Infanrix Hexa","Biological: Menjugate","Biological: Prevenar"]}],"interventions":[{"name":"Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)","otherNames":[]},{"name":"Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)","otherNames":[]},{"name":"Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)","otherNames":[]},{"name":"Infanrix Hexa","otherNames":[]},{"name":"Menjugate","otherNames":[]},{"name":"Prevenar","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy 2-month old infants (55-89 days, inclusive)\n\nExclusion Criteria:\n\n* Prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens)\n* Previous ascertained or suspected disease caused by N. meningitidis\n* History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;\n* Any serious chronic or progressive disease\n* Known or suspected impairment or alteration of the immune system","healthyVolunteers":true,"sex":"ALL","minimumAge":"55 Days","maximumAge":"89 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination","description":"The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null},{"groupId":"OG001","value":"1.19","spread":null},{"groupId":"OG002","value":"1.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"1.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"598","spread":null},{"groupId":"OG001","value":"681","spread":null},{"groupId":"OG002","value":"607","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null},{"groupId":"OG001","value":"1.06","spread":null},{"groupId":"OG002","value":"1.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)","description":"The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)","description":"The immunogenicity was evaluated to assess the consistency of the immune response from three lots of rMenB+OMV NZ in terms of percentage of subjects as measured by hSBA titer ≥1:5 when given to healthy infants at 2, 4, and 6 months of age, at 1 month after the third vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ","description":"The immunogenicity was assessed in terms of prevalence of meningococcal B antibodies as measured by the hSBA, at baseline and at one month after the third vaccination, in the subjects that received routine infant vaccines without rMenB+OMV NZ.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":null},{"groupId":"OG001","value":"1.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":null},{"groupId":"OG001","value":"1.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"635","spread":null},{"groupId":"OG001","value":"1.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"1.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"1.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)","description":"The immunogenicity was evaluated to characterize the immune response against vaccine antigen 287-953, as measured by ELISA at one month after third vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"22","spread":null},{"groupId":"OG004","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3149","spread":null},{"groupId":"OG001","value":"3484","spread":null},{"groupId":"OG002","value":"3103","spread":null},{"groupId":"OG003","value":"3370","spread":null},{"groupId":"OG004","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations for Antigens (Pertussis Components) for the Routine Vaccinations","description":"Immunogenicity of the pertussis components (PT, FHA, pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after third vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.98","spread":null},{"groupId":"OG001","value":"9.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"5.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.82","spread":null},{"groupId":"OG001","value":"2.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Antibody Response Against the Routine Antigens","description":"The immunogenicity of routine infant vaccines when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age and of the routine infant vaccines given without rMenB+OMV NZ at 1 month after third vaccination with B pertussis, diptheria and tetanus toxoid, H influenza type b, Hepatitis B antigens was measured by ELISA (Enzyme-linked immunosorbent assay) and for polio type 1, type 2 and type 3 by neutralization test (NT)(\\>=1:8). Diptheria and Tetanus: primary endpoint ELISA \\>=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA\\>=1.0 IU/mL.\n\nHepB (HBV):primary endpoint ELISA \\>=10 mU/mL. PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.PNC \\>=0.35 mcg/ml","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Fourfold Increase in Antibody Concentrations Against the Routine Antigens","description":"Immunogenicity was assessed in terms of the percentages of subjects with fourfold increase in antibody concentrations against the routine pertussis antigens FHA (Filamentous Hemagglutinin), Pertactin and PT (Pertussis Toxoid).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Fourfold Rise in hSBA Titers After Three Doses of rMenB+OMV NZ Vaccination","description":"Immunogenicity was assessed in terms of the percentages of subjects with fourfold rise in hSBA titers after the three doses of rMenB+OMV NZ (lot 1 or lot 2 or lot 3) vaccination at 2, 4 and 6 months of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"71","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With hSBA Titers ≥1:8","description":"Immunogenicity was assessed in terms of the percentages of subjects achieving hSBA titers ≥1:8 at one month after third vaccination with rMenB (lot 1 or lot 2 or lot 3) against the three vaccine strains.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"72","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Adverse Events After Receiving Three Doses of rMenB+OMV NZ Vaccine","description":"The safety and tolerability of three doses of rMenB+OMV NZ when given concomitantly with routine infant vaccines at 2, 4 and 6 months of age was assessed by the number of subjects reporting solicited local and systemic adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2388","spread":null},{"groupId":"OG001","value":"443","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2147","spread":null},{"groupId":"OG001","value":"266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2049","spread":null},{"groupId":"OG001","value":"261","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1908","spread":null},{"groupId":"OG001","value":"227","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1174","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2450","spread":null},{"groupId":"OG001","value":"459","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1787","spread":null},{"groupId":"OG001","value":"257","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2159","spread":null},{"groupId":"OG001","value":"353","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"662","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1086","spread":null},{"groupId":"OG001","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2296","spread":null},{"groupId":"OG001","value":"370","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2109","spread":null},{"groupId":"OG001","value":"352","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"318","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1912","spread":null},{"groupId":"OG001","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2302","spread":null},{"groupId":"OG001","value":"325","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2302","spread":null},{"groupId":"OG001","value":"325","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2240","spread":null},{"groupId":"OG001","value":"314","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":70,"n":832},"commonTop":["Irritability","Injection site erythema","Somnolence","Injection site pain","Crying"]}}}